Ken Griffin Kazia Therapeutics LTD Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Kazia Therapeutics LTD stock. As of the latest transaction made, Citadel Advisors LLC holds 24,000 shares of KZIA stock, worth $7,680. This represents 0.0% of its overall portfolio holdings.
Number of Shares
24,000Holding current value
$7,680% of portfolio
0.0%Shares
8 transactions
Others Institutions Holding KZIA
# of Institutions
13Shares Held
328KCall Options Held
24KPut Options Held
0-
Morgan Stanley New York, NY201KShares$64,3460.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA41.5KShares$13,2720.0% of portfolio
-
Virtu Financial LLC New York, NY39.3KShares$12,5680.0% of portfolio
-
Ubs Group Ag23.3KShares$7,4670.0% of portfolio
-
Rhumbline Advisers Boston, MA17.6KShares$5,6360.0% of portfolio
About KAZIA THERAPEUTICS LTD
- Ticker KZIA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,111,300
- Market Cap $4.84M
- Description
- Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various...